Cargando…
Selegiline reduces daytime sleepiness in patients with Parkinson's disease
OBJECTIVES: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given...
Autores principales: | Gallazzi, Marco, Mauri, Marco, Bianchi, Maria Laura, Riboldazzi, Giulio, Princiotta Cariddi, Lucia, Carimati, Federico, Rebecchi, Valentina, Versino, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119812/ https://www.ncbi.nlm.nih.gov/pubmed/33759401 http://dx.doi.org/10.1002/brb3.1880 |
Ejemplares similares
-
Vitamin D, Chronic Migraine, and Extracranial Pain: Is There a Link? Data From an Observational Study
por: Rebecchi, Valentina, et al.
Publicado: (2021) -
An Example of a Stroke Unit Reshaping in the Context of a Regional Hub and Spoke System in the COVID-19 Era
por: Candeloro, Elisa, et al.
Publicado: (2020) -
Selegiline improves excessive daytime sleepiness in Parkinson's disease: an open-label observational study
por: Zhang, Jinru, et al.
Publicado: (2022) -
Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition
por: Princiotta Cariddi, Lucia, et al.
Publicado: (2022) -
Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient
por: Princiotta Cariddi, Lucia, et al.
Publicado: (2020)